沈阳东城痘痘医院具体位置沈阳市专业治疗脂溢性脱发的医院,沈阳治皮肤过敏疗效好的医院,沈阳荨麻疹应该怎样治,沈阳狐臭除费用大概多少,沈阳中医治疗斑秃价格,沈阳市治掉头发比较好的医院,沈阳哪家医院看风疹块比较好

LOS ANGELES, Dec. 21 (Xinhua) -- The late Apple co-founder Steve Jobs will be honored posthumously with a Grammy award for his contributions to music technology, The Recording Academy announced on Wednesday.Jobs, who passed away Oct. 5 of pancreatic cancer, will receive a Trustees Award for helping create products "that transformed the way we consume music, TV, movies and books," the academy said in a prepared statement.The Apple Computer Inc. first received a Technical Grammy Award in 2002, for contributions of outstanding technical significance to the recording field, the academy said.Along with Jobs, bandleader and composer Dave Bartholomew, recording engineer Rudy Van Gelder will also receive the award.The academy also picked the Allman Brothers, Glen Campbell, Diana Ross and Brazilian pianist/singer/guitarist Antonio Carlos Jobim as recipients of Lifetime Achievement Awards. Jobim was known for composing "The Girl from Ipanema," a worldwide hit in the mid-1960s which won a Grammy for Record of the Year in 1965.Other artists, including trumpeter Wayne Jackson, saxophonist Andrew Love of the Memphis Horns,country legend George Jones,and the late Gil Scott-Heron were also named as recipients.German sound-technology firm Celemony and the late audio engineer Roger Nichols, who worked with artists including Ross, Placido Domingo, James Taylor and Stevie Wonder, were recognized with Grammy Technical Awards."This year's honorees offer a variety of brilliance, contributions and lasting impressions on our culture," said President/CEO of The Recording Academy Neil Portnow. "It is an honor to recognize such a diverse group of individuals whose talents and achievements have had an indelible impact on our industry."The honorees will be formally acknowledged during the 54th Annual Grammy Awards telecast at Staples Center in downtown Los Angeles on Feb. 12, 2012.

BEIJING, Nov. 30 (Xinhua) -- China's efforts to fight AIDS are impressive and its experience can be shared, according to Michel Sidibe, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS)."We have seen progress in terms of new infections. The number of people going into treatment is increasing and the mortality rate is going down very quickly in China," Sidibe said during an interview with Xinhua on Wednesday.Sidibe said he was impressed by the country's political leadership and commitment to controlling AIDS.According to UNAIDS, the country has reported a 60-percent reduction in deaths due to AIDS over the past eight years.New HIV infection cases in China have been reduced from 70,000 people annually in 2005 to around 48,000 in 2011, according to the country's health department."However, China's success will not only be measured by what it has done for the Chinese people," Sidibe said.China has successful experience in reducing new HIV infections among intravenous drug users, which can be shared with the rest of the world, particularly east Europe and south Asia where HIV infections among drug abusers is a major challenge, he said.Sidibe suggested that the country should work with the rest of the developing world, particularly Africa, in fighting AIDS.A partnership between China and Africa will make a "big, big difference" in reducing AIDS mortality rates and introducing new technology and perspectives in Africa, said the official who had worked for UN in several African countries for more than two decades.Admitting the challenges of funding AIDS control programs during the current global economic downturn, Sidibe called for global solidarity and increasing shared responsibilities among countries."It is a critical moment now. It is not a time to stop investment but to redouble our efforts, to make sure that we will continue to make progress in the fight against HIV," Sidibe said."Getting to Zero" has been chosen as the main theme of World AIDS Day for the next five years, referring to UNAIDS' vision of "zero new HIV infections, zero discrimination and zero AIDS-related deaths."Sidibe met with Li Congjun, president of the Xinhua News Agency, on Wednesday before the interview. The agency has launched a global media campaign in cooperation with UNAIDS to raise public awareness about HIV/AIDS."The partnership (with Xinhua) is not only about writing news about HIV. It is about helping people to change their attitude and make decisions to help protect themselves," Sidibe said.

SAN FRANCISCO, Oct. 17 (Xinhua) -- Apple on Monday announced that it has sold more than four million of its new iPhone 4S, three days after the launch last Friday."IPhone 4S is off to a great start with more than four million sold in its first weekend--the most ever for a phone and more than double the iPhone 4 launch during its first three days," said Philip Schiller, Apple's senior vice president of worldwide product marketing.In addition, more than 25 million customers are already using iOS 5, the latest version of the mobile operating system powering Apple's mobile devices, since it was released last Wednesday; and more than 20 million customers have signed up for iCloud, the cloud service designed to store and sync data for download to multiple devices, said the company in the statement.The iPhone 4S, which looks the same as the iPhone 4, has major hardware upgrade inside, including a faster chip, a higher- resolution camera and Siri intelligent voice control.Last Friday, AT&T and Sprint, two iPhone wireless carriers in the United States, said they have seen record daily sales with the launch of the iPhone 4S.The lasted Apple smartphone is currently on sale in the U.S., Canada, France, Germany, Japan and Britain, and will be available in 22 more countries on Oct. 28. Apple said the phone will be on sale in more than 70 countries and regions by the end of this year.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.